Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine in idiopathic restless legs syndrome
NCT00275236Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2005
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rotigotine in restless legs syndrome (RLS), sponsored by UCB. Primary endpoint: Periodic Limb Movement Index at 7 weeks. Started Nov 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00275236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275236.